Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali

CRL shall invest another Rs. 200 crore for creation of additional beds

Pfizer Q1 2025 revenue drops 8% to $13.7 billion

Delivers robust earnings performance, successfully navigating a dynamic environment

Injection filter needle market to reach $1.73 billion in 2025

Rising demands and advancements in eye care drive growth

Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study

Indegene launches AI platform Cortex

This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain

Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab

FDA approves EMBLAVEO for the treatment of adults with complicated intra-abdominal infections

EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA

FDA approves Roche’s Susvimo as the first and only continuous delivery treatment diabetes-related blindness

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)

Carbogen Amcis appoints Stephan Fritschi as CEO

Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.